AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8853769 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin suspension given pre-prandially
Number of subjects: 79
Study 8853769 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin suspension given post-prandially
Number of subjects: 79
Study 8853769 — intervention group
Group type: EXPERIMENTAL
Intervention: Good compliance group
Number of subjects: 79
Study 8853769 — intervention group
Group type: COMPARATOR
Intervention: Others completing the protocol
Number of subjects: 79
Study 1377333 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (3 x 1000 mg over 8 h)
Number of subjects: 0
Study 1377333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6725527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg orally)
Number of subjects: 20
Study 6725527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg orally) plus Bromocriptine
Number of subjects: 20
Study 6725527 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg orally) plus Bromocriptine
Number of subjects: 20
Study 6725527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31106714 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated hand hygiene monitoring system (AHHMS) with supplementary strategies
Number of subjects: 93
Study 31106714 — intervention group
Group type: COMPARATOR
Intervention: Automated hand hygiene monitoring system (AHHMS) without supplementary activities
Number of subjects: 93
Study 31106714 — intervention group
Group type: COMPARATOR
Intervention: Non-Clostridioides difficile HAIs
Number of subjects: 93
Study 31106714 — intervention group
Group type: COMPARATOR
Intervention: Clostridioides difficile infections
Number of subjects: 93
Study 30012049 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase injection
Number of subjects: 93
Study 30012049 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle fasciotomy
Number of subjects: 93
Study 27452767 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP withdrawal for 2 weeks
Number of subjects: 149
Study 27452767 — intervention group
Group type: COMPARATOR
Intervention: CPAP continuation for 2 weeks
Number of subjects: 149
Study 23861153 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy (WBRT) alone
Number of subjects: 176
Study 22388713 — intervention group
Group type: EXPERIMENTAL
Intervention: Head orthesis therapy
Number of subjects: 40
Study 22388713 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants without head deformities)
Number of subjects: 40
Study 19998218 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-cytobrushing
Number of subjects: 37
Study 19998218 — intervention group
Group type: COMPARATOR
Intervention: EUS-FNA
Number of subjects: 37
Study 18693659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (25 microg)
Number of subjects: 64
Study 18693659 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (2.5 mg)
Number of subjects: 64
Study 15960717 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils intubation fibrescope
Number of subjects: 20
Study 15960717 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 20
Study 12566364 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided percutaneous transluminal coronary angioplasty (aggressive PTCA)
Number of subjects: 254
Study 12566364 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 254
Study 10548188 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmafiltration (PF)
Number of subjects: 30
Study 10548188 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 8517061 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g vigabatrin for 2 months
Number of subjects: 10
Study 8517061 — intervention group
Group type: EXPERIMENTAL
Intervention: titrated optimal dosage vigabatrin for another 2 months
Number of subjects: 10
Study 8517061 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG mapping after 2 months vigabatrin
Number of subjects: 10
Study 8517061 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP mapping after 2 months vigabatrin
Number of subjects: 10
Study 3481814 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion
Number of subjects: 0
Study 3481814 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ANG II and NA infusion
Number of subjects: 0
Study 3481814 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 31736269 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone implant (Ozurdex)
Number of subjects: 18
Study 31736269 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (Lucentis)
Number of subjects: 18
Study 29164797 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696) 200 mg twice per day, initiated and up-titrated over 3 or 6 weeks
Number of subjects: 498
Study 29164797 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual up-titration (6 weeks) of sacubitril/valsartan
Number of subjects: 498
Study 29164797 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan (LCZ696) 200 mg twice per day
Number of subjects: 498
Study 27595023 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program 1
Number of subjects: 82
Study 27595023 — intervention group
Group type: COMPARATOR
Intervention: Home visiting program 2
Number of subjects: 82
Study 25618791 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 kcal/day (MOD)
Number of subjects: 53
Study 25618791 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 kcal/day (HIGH)
Number of subjects: 53
Study 25618791 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 53
Study 24022747 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate and intraarticular glucocorticoids plus adalimumab
Number of subjects: 180
Study 24022747 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and intraarticular glucocorticoids plus placebo/adalimumab
Number of subjects: 180
Study 24022747 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline M-ficolin level in the lowest quartile
Number of subjects: 180
Study 21511212 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS delivered to the left dorsolateral prefrontal cortex
Number of subjects: 38
Study 21511212 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 38
Study 19366965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranirestat 20 mg/day
Number of subjects: 549
Study 19366965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranirestat 40 mg/day
Number of subjects: 549
Study 19366965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549
Study 16935343 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-cobalt gray equivalent (CGE) proton radiation
Number of subjects: 166
Study 16935343 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-cobalt gray equivalent (CGE) proton radiation
Number of subjects: 166
Study 16935343 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between the two doses)
Number of subjects: 166
Study 15293170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV) applied for at least six hours per day in addition to standard COPD treatment.
Number of subjects: 300
Study 15293170 — intervention group
Group type: COMPARATOR
Intervention: Standard COPD treatment (Control group).
Number of subjects: 300
Study 15293170 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV (Intervention group).
Number of subjects: 300
Study 11739062 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics
Number of subjects: 0
Study 11739062 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10584721 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirecumbent body position
Number of subjects: 86
Study 10584721 — intervention group
Group type: COMPARATOR
Intervention: Supine body position
Number of subjects: 86
Study 8004320 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐CPAP (mouth closed)
Number of subjects: 6
Study 8004320 — intervention group
Group type: EXPERIMENTAL
Intervention: face mask CPAP (f‐CPAP)
Number of subjects: 6
Study 2813482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine infusion after bolus loading doses
Number of subjects: 7
Study 2813482 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion after bolus loading doses
Number of subjects: 7
Study 2813482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine infusion
Number of subjects: 7
Study 4586044 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (400 mug daily, intranasally)
Number of subjects: 29
Study 31579978 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 60
Study 31579978 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 60
Study 31579978 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Silymarin and Doxycycline
Number of subjects: 60
Study 28735067 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan/cetuximab followed by FOLFOX-4 (arm A)
Number of subjects: 110
Study 28735067 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 followed by irinotecan/cetuximab (arm B)
Number of subjects: 110
Study 28735067 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm A)
Number of subjects: 110
Study 25327537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered implants (test group)
Number of subjects: 10
Study 25327537 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical implants (control group)
Number of subjects: 10
Study 23234265 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle (knee flexion) for three sets of 30 seconds with 30 seconds rest intervals
Number of subjects: 27
Study 23234265 — intervention group
Group type: COMPARATOR
Intervention: Control (no stretching)
Number of subjects: 27
Study 23234265 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle
Number of subjects: 27
Study 21505349 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS100 (Losartan 100 mg q.d.)
Number of subjects: 20
Study 21505349 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS200 (Losartan 100 mg b.i.d.)
Number of subjects: 20
Study 21505349 — intervention group
Group type: EXPERIMENTAL
Intervention: LOS100 + LIS20 (Losartan 100 mg q.d. + Lisinopril 20 mg q.d.)
Number of subjects: 20
Study 18259807 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thyroidectomy (VAT)
Number of subjects: 65
Study 18259807 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroidectomy (CT)
Number of subjects: 65
Study 17224949 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% cyclosporine A in preservative-free artificial tears
Number of subjects: 20
Study 17224949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 14499682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride and tamsulosin matched placebo for the remaining 12 weeks (DT24+D12)
Number of subjects: 327
Study 14499682 — intervention group
Group type: COMPARATOR
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 36 weeks (DT36)
Number of subjects: 327
Study 14499682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg dutasteride and 0.4mg tamsulosin for 24 weeks followed by dutasteride monotherapy
Number of subjects: 327
Study 14499682 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of tamsulosin therapy at week 24
Number of subjects: 327
Study 11134877 — intervention group
Group type: EXPERIMENTAL
Intervention: CeeOn 912 using Nichamin implantation forceps
Number of subjects: 40
Study 11134877 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof MA30BA using Buratto implantation forceps
Number of subjects: 40
Study 11134877 — intervention group
Group type: EXPERIMENTAL
Intervention: SI‐55NB using Fine Universal II Folder
Number of subjects: 40
Study 11134877 — intervention group
Group type: EXPERIMENTAL
Intervention: SI‐55NB using AMO Unfolder
Number of subjects: 40
Study 11134877 — intervention group
Group type: COMPARATOR
Intervention: SI‐55NB with Unfolder vs Fine folder
Number of subjects: 40
Study 9113009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8-1.1 g/kg daily adjusted for age)
Number of subjects: 191
Study 9113009 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard protein intake)
Number of subjects: 191
Study 7690093 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 300 mg
Number of subjects: 16
Study 7690093 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg
Number of subjects: 16
Study 7690093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3527810 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1114
Study 3527810 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1114
Study 3527810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1114
Study 3527810 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment within 6 hours of chest pain onset
Number of subjects: 1114
Study 3527810 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment 6 to 12 hours after chest pain onset
Number of subjects: 1114
Study 30062657 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 177
Study 30062657 — intervention group
Group type: COMPARATOR
Intervention: Control group (1/0 monofilament polypropylene, 3/0 polyglactin, 3/0 polypropylene)
Number of subjects: 177
Study 30062657 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study 25805891 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized caregiver support provided by a team led by a care coordinator of the person with dementia
Number of subjects: 61
Study 25805891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 61
Study 24500147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (1000 mg Ca)
Number of subjects: 7569
Study 24500147 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk alleles from a score of 6 WC-associated SNPs with dietary calcium intake (1000 mg Ca)
Number of subjects: 7569
Study 24500147 — intervention group
Group type: COMPARATOR
Intervention: Dietary calcium intake
Number of subjects: 7569
Study 22936457 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 48
Study 22936457 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 48
Study 20929598 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg, b.i.d.)
Number of subjects: 49
Study 20929598 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (100 μg, b.i.d.)
Number of subjects: 49
Study 18356628 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0
Study 18356628 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug therapy
Number of subjects: 0
Study 18356628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fibrate or nicotinic acid with LDL cholesterol-lowering drug
Number of subjects: 0
Study 18356628 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol-lowering drug therapy
Number of subjects: 0
Study 16038024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Xeloda 1,000 mg/m2 administered twice daily from d 1 to 14
Number of subjects: 131
Study 16038024 — intervention group
Group type: COMPARATOR
Intervention: Calcium folinate (CF) 200 mg/m2 as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5
Number of subjects: 131
Study 12447029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day for 6 weeks, then up to 80 mg/day for 8 weeks)
Number of subjects: 43
Study 12447029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine responders (n = 11)
Number of subjects: 43
Study 12447029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 43
Study 12447029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10337457 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L. (Iscador Qu Spezial and Viscum album QuFrF)
Number of subjects: 47
Study 10337457 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L.
Number of subjects: 47
Study 9110055 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg daily, increased to a maximum of 16 mg daily)
Number of subjects: 28
Study 9110055 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 28
Study 1943500 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (6 g per day)
Number of subjects: 15
Study 7015693 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 (30 mg/m2 iv for 5 days with 7-14 day intervals)
Number of subjects: 61
Study 7015693 — intervention group
Group type: EXPERIMENTAL
Intervention: VM-26 (50 mg/m2 two injections a week for 4-6 weeks)
Number of subjects: 61
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: MD + DEP (Mediterranean Diet + Dynamic Exercise Program)
Number of subjects: 144
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: DEP (Dynamic Exercise Program)
Number of subjects: 144
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: MD (Mediterranean Diet)
Number of subjects: 144
Study 31145222 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 144
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: MD + DEP
Number of subjects: 144
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: DEP
Number of subjects: 144
Study 31145222 — intervention group
Group type: EXPERIMENTAL
Intervention: MD
Number of subjects: 144
Study 31348336 — intervention group
Group type: EXPERIMENTAL
Intervention: Restylane 2
Number of subjects: 82
Study 31348336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermalax DEEP
Number of subjects: 82
Study 28807367 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum therapy for OCCC
Number of subjects: 9531
Study 28807367 — intervention group
Group type: COMPARATOR
Intervention: Platinum therapy for SOC
Number of subjects: 9531
Study 28807367 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative therapy with weekly Paclitaxel
Number of subjects: 9531
Study 28807367 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 9531
Study 26189201 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS (1-Hz, 20 minutes, 10 sessions)
Number of subjects: 30
Study 26189201 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 26189201 — intervention group
Group type: COMPARATOR
Intervention: rTMS vs Sham
Number of subjects: 30
Study 24300820 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatimer acetate (GA) 20 mg daily for at least 12 months
Number of subjects: 534
Study 24300820 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐Β 44 mg three times a week
Number of subjects: 534
Study 20422199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-proanthocyanidin (PA) red de-alcoholised wine (DAW) (500 mL/die, PA dose = 7 mg/kg)
Number of subjects: 21
Study 20422199 — intervention group
Group type: COMPARATOR
Intervention: Low-proanthocyanidin rosé de-alcoholised wine (DAW) (500 mL/die, PA dose = 0.45 mg/kg)
Number of subjects: 21
Study 19478258 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg/day for six weeks
Number of subjects: 42
Study 19478258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17960402 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 9 months
Number of subjects: 48
Study 17960402 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 9 months
Number of subjects: 48
Study 15009707 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,4-dinitrochlorobenzene sensitization after UVR exposure
Number of subjects: 13
Study 15009707 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylcyclopropenone sensitization without UVR exposure
Number of subjects: 13
Study 15009707 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between Sigma DN and Sigma DP
Number of subjects: 13
Study 11706726 — intervention group
Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 60
Study 11706726 — intervention group
Group type: COMPARATOR
Intervention: Unicompartmental arthroplasty (UKA)
Number of subjects: 60
Study 9212590 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (one dose administration)
Number of subjects: 0
Study 9212590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha 2b treatment (6-month course)
Number of subjects: 0
Study 8491012 — intervention group
Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg t.i.d.)
Number of subjects: 2304
Study 8491012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2304
Study 2979683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 18
Study 2979683 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg or 800 mg
Number of subjects: 18
Study 2979683 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 18
Study 31163319 — intervention group
Group type: EXPERIMENTAL
Intervention: Training condition (gaze-contingent music reward design)
Number of subjects: 85
Study 31163319 — intervention group
Group type: COMPARATOR
Intervention: Yoked control condition
Number of subjects: 85
Study 29168087 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Attention Mediated Learning (JAML) intervention
Number of subjects: 144
Study 29168087 — intervention group
Group type: COMPARATOR
Intervention: Community control
Number of subjects: 144
Study 26197839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (single dose during cardiac catheterisation)
Number of subjects: 20